Race and Survival Following Brachytherapy-Based Treatment for Men With Localized or Locally Advanced Adenocarcinoma of the Prostate
Purpose We investigated whether race was associated with risk of death following brachytherapy-based treatment for localized prostate cancer, adjusting for age, cardiovascular comorbidity, treatment, and established prostate cancer prognostic factors. Methods The study cohort was composed of 5,360 m...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2011-11, Vol.81 (4), p.e345-e350 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e350 |
|---|---|
| container_issue | 4 |
| container_start_page | e345 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 81 |
| creator | Winkfield, Karen M., M.D., Ph.D Chen, Ming-Hui, Ph.D Dosoretz, Daniel E., M.D Salenius, Sharon A., M.P.H Katin, Michael, M.D Ross, Rudi, B.S D’Amico, Anthony V., M.D., Ph.D |
| description | Purpose We investigated whether race was associated with risk of death following brachytherapy-based treatment for localized prostate cancer, adjusting for age, cardiovascular comorbidity, treatment, and established prostate cancer prognostic factors. Methods The study cohort was composed of 5,360 men with clinical stage T1-3N0M0 prostate cancer who underwent brachytherapy-based treatment at 20 centers within the 21st Century Oncology consortium. Cox regression multivariable analysis was used to evaluate the risk of death in African-American and Hispanic men compared to that in Caucasian men, adjusting for age, pretreatment prostate-specific antigen (PSA) level, Gleason score, clinical T stage, year and type of treatment, median income, and cardiovascular comorbidities. Results After a median follow-up of 3 years, there were 673 deaths. African-American and Hispanic races were significantly associated with an increased risk of all-cause mortality (ACM) (adjusted hazard ratio, 1.77 and 1.79; 95% confidence intervals, 1.3–2.5 and 1.2–2.7; p < 0.001 and p = 0.005, respectively). Other factors significantly associated with an increased risk of death included age ( p < 0.001), Gleason score of 8 to 10 ( p = 0.04), year of brachytherapy ( p < 0.001), and history of myocardial infarction treated with stent or coronary artery bypass graft ( p < 0.001). Conclusions After adjustment for prostate cancer prognostic factors, age, income level, and revascularized cardiovascular comorbidities, African-American and Hispanic races were associated with higher ACM in men with prostate cancer. Additional causative factors need to be identified. |
| doi_str_mv | 10.1016/j.ijrobp.2011.02.022 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22054389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301611003233</els_id><sourcerecordid>901304605</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-90a1b87626783e8017e9f3b3c512db24de36d761565d541e2e42305587b87a443</originalsourceid><addsrcrecordid>eNqFkk2LFDEQhoMo7rj6D0QCHjz1mM_-uAizi6vCiOKu6C2k09VO2u5kTLpH2qt_3LS9evAiBEKK562q1FsIPaZkSwnNn3db2wVfH7eMULolLB12B21oWVQZl_LzXbQhPCcZT_AZehBjR0giC3EfnTEqqSB5vkE_P2gDWLsGX0_hZE-6x1e-7_13677gi6DNYR4PEPRxzi50hAbfBNDjAG7ErQ_4LTj8yY4HvPdG9_ZHAlL096Of8a45aWdSbNeAS7FgrPODxr7FKSl-H3wc9QgP0b1W9xEe3d7n6OPVy5vL19n-3as3l7t9ZoQQY1YRTeuyyFlelBxKQguoWl5zIylraiYa4HlT5FTmspGCAgPBOJGyLJJKC8HP0dM1byprVTR2BHMw3jkwo2KMSMHLKlHPVuoY_LcJ4qgGGw30vXbgp6gqQjkROZGJFCtp0kdigFYdgx10mBUlavFIdWr1SC0eKcLSYUn25LbAVA_Q_BX9MSUBL1YA0jBOFsLSKyyDtGFptfH2fxX-TWB662wy5SvMEDs_BZcGraiKSaCulz1Z1oRSQjjjnP8C7tK4jQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>901304605</pqid></control><display><type>article</type><title>Race and Survival Following Brachytherapy-Based Treatment for Men With Localized or Locally Advanced Adenocarcinoma of the Prostate</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Winkfield, Karen M., M.D., Ph.D ; Chen, Ming-Hui, Ph.D ; Dosoretz, Daniel E., M.D ; Salenius, Sharon A., M.P.H ; Katin, Michael, M.D ; Ross, Rudi, B.S ; D’Amico, Anthony V., M.D., Ph.D</creator><creatorcontrib>Winkfield, Karen M., M.D., Ph.D ; Chen, Ming-Hui, Ph.D ; Dosoretz, Daniel E., M.D ; Salenius, Sharon A., M.P.H ; Katin, Michael, M.D ; Ross, Rudi, B.S ; D’Amico, Anthony V., M.D., Ph.D</creatorcontrib><description>Purpose We investigated whether race was associated with risk of death following brachytherapy-based treatment for localized prostate cancer, adjusting for age, cardiovascular comorbidity, treatment, and established prostate cancer prognostic factors. Methods The study cohort was composed of 5,360 men with clinical stage T1-3N0M0 prostate cancer who underwent brachytherapy-based treatment at 20 centers within the 21st Century Oncology consortium. Cox regression multivariable analysis was used to evaluate the risk of death in African-American and Hispanic men compared to that in Caucasian men, adjusting for age, pretreatment prostate-specific antigen (PSA) level, Gleason score, clinical T stage, year and type of treatment, median income, and cardiovascular comorbidities. Results After a median follow-up of 3 years, there were 673 deaths. African-American and Hispanic races were significantly associated with an increased risk of all-cause mortality (ACM) (adjusted hazard ratio, 1.77 and 1.79; 95% confidence intervals, 1.3–2.5 and 1.2–2.7; p < 0.001 and p = 0.005, respectively). Other factors significantly associated with an increased risk of death included age ( p < 0.001), Gleason score of 8 to 10 ( p = 0.04), year of brachytherapy ( p < 0.001), and history of myocardial infarction treated with stent or coronary artery bypass graft ( p < 0.001). Conclusions After adjustment for prostate cancer prognostic factors, age, income level, and revascularized cardiovascular comorbidities, African-American and Hispanic races were associated with higher ACM in men with prostate cancer. Additional causative factors need to be identified.</description><identifier>ISSN: 0360-3016</identifier><identifier>ISSN: 1879-355X</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2011.02.022</identifier><identifier>PMID: 21514066</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenocarcinoma - ethnology ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - radiotherapy ; Aged ; Androgen Antagonists - therapeutic use ; ANTIGENS ; Black or African American ; Black People ; BRACHYTHERAPY ; Brachytherapy - mortality ; BYPASSES ; CARCINOMAS ; Cardiac comorbidity ; Cause of Death ; Cohort Studies ; CORONARIES ; DEATH ; HAZARDS ; Hematology, Oncology and Palliative Medicine ; Hispanic or Latino ; Humans ; Male ; MEN ; MORTALITY ; MYOCARDIAL INFARCTION ; Myocardial Infarction - mortality ; Myocardial Infarction - therapy ; Neoplasm Grading ; Neoplasm Staging ; Prognosis ; PROSTATE ; Prostate brachytherapy ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - ethnology ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - radiotherapy ; Racial disparities ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; Regression Analysis ; Risk Factors ; Socioeconomic Factors ; Treatment Outcome ; Treatment outcomes ; White People</subject><ispartof>International journal of radiation oncology, biology, physics, 2011-11, Vol.81 (4), p.e345-e350</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-90a1b87626783e8017e9f3b3c512db24de36d761565d541e2e42305587b87a443</citedby><cites>FETCH-LOGICAL-c444t-90a1b87626783e8017e9f3b3c512db24de36d761565d541e2e42305587b87a443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2011.02.022$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21514066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22054389$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Winkfield, Karen M., M.D., Ph.D</creatorcontrib><creatorcontrib>Chen, Ming-Hui, Ph.D</creatorcontrib><creatorcontrib>Dosoretz, Daniel E., M.D</creatorcontrib><creatorcontrib>Salenius, Sharon A., M.P.H</creatorcontrib><creatorcontrib>Katin, Michael, M.D</creatorcontrib><creatorcontrib>Ross, Rudi, B.S</creatorcontrib><creatorcontrib>D’Amico, Anthony V., M.D., Ph.D</creatorcontrib><title>Race and Survival Following Brachytherapy-Based Treatment for Men With Localized or Locally Advanced Adenocarcinoma of the Prostate</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose We investigated whether race was associated with risk of death following brachytherapy-based treatment for localized prostate cancer, adjusting for age, cardiovascular comorbidity, treatment, and established prostate cancer prognostic factors. Methods The study cohort was composed of 5,360 men with clinical stage T1-3N0M0 prostate cancer who underwent brachytherapy-based treatment at 20 centers within the 21st Century Oncology consortium. Cox regression multivariable analysis was used to evaluate the risk of death in African-American and Hispanic men compared to that in Caucasian men, adjusting for age, pretreatment prostate-specific antigen (PSA) level, Gleason score, clinical T stage, year and type of treatment, median income, and cardiovascular comorbidities. Results After a median follow-up of 3 years, there were 673 deaths. African-American and Hispanic races were significantly associated with an increased risk of all-cause mortality (ACM) (adjusted hazard ratio, 1.77 and 1.79; 95% confidence intervals, 1.3–2.5 and 1.2–2.7; p < 0.001 and p = 0.005, respectively). Other factors significantly associated with an increased risk of death included age ( p < 0.001), Gleason score of 8 to 10 ( p = 0.04), year of brachytherapy ( p < 0.001), and history of myocardial infarction treated with stent or coronary artery bypass graft ( p < 0.001). Conclusions After adjustment for prostate cancer prognostic factors, age, income level, and revascularized cardiovascular comorbidities, African-American and Hispanic races were associated with higher ACM in men with prostate cancer. Additional causative factors need to be identified.</description><subject>Adenocarcinoma - ethnology</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Aged</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>ANTIGENS</subject><subject>Black or African American</subject><subject>Black People</subject><subject>BRACHYTHERAPY</subject><subject>Brachytherapy - mortality</subject><subject>BYPASSES</subject><subject>CARCINOMAS</subject><subject>Cardiac comorbidity</subject><subject>Cause of Death</subject><subject>Cohort Studies</subject><subject>CORONARIES</subject><subject>DEATH</subject><subject>HAZARDS</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hispanic or Latino</subject><subject>Humans</subject><subject>Male</subject><subject>MEN</subject><subject>MORTALITY</subject><subject>MYOCARDIAL INFARCTION</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocardial Infarction - therapy</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>PROSTATE</subject><subject>Prostate brachytherapy</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - ethnology</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Racial disparities</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>Regression Analysis</subject><subject>Risk Factors</subject><subject>Socioeconomic Factors</subject><subject>Treatment Outcome</subject><subject>Treatment outcomes</subject><subject>White People</subject><issn>0360-3016</issn><issn>1879-355X</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk2LFDEQhoMo7rj6D0QCHjz1mM_-uAizi6vCiOKu6C2k09VO2u5kTLpH2qt_3LS9evAiBEKK562q1FsIPaZkSwnNn3db2wVfH7eMULolLB12B21oWVQZl_LzXbQhPCcZT_AZehBjR0giC3EfnTEqqSB5vkE_P2gDWLsGX0_hZE-6x1e-7_13677gi6DNYR4PEPRxzi50hAbfBNDjAG7ErQ_4LTj8yY4HvPdG9_ZHAlL096Of8a45aWdSbNeAS7FgrPODxr7FKSl-H3wc9QgP0b1W9xEe3d7n6OPVy5vL19n-3as3l7t9ZoQQY1YRTeuyyFlelBxKQguoWl5zIylraiYa4HlT5FTmspGCAgPBOJGyLJJKC8HP0dM1byprVTR2BHMw3jkwo2KMSMHLKlHPVuoY_LcJ4qgGGw30vXbgp6gqQjkROZGJFCtp0kdigFYdgx10mBUlavFIdWr1SC0eKcLSYUn25LbAVA_Q_BX9MSUBL1YA0jBOFsLSKyyDtGFptfH2fxX-TWB662wy5SvMEDs_BZcGraiKSaCulz1Z1oRSQjjjnP8C7tK4jQ</recordid><startdate>20111115</startdate><enddate>20111115</enddate><creator>Winkfield, Karen M., M.D., Ph.D</creator><creator>Chen, Ming-Hui, Ph.D</creator><creator>Dosoretz, Daniel E., M.D</creator><creator>Salenius, Sharon A., M.P.H</creator><creator>Katin, Michael, M.D</creator><creator>Ross, Rudi, B.S</creator><creator>D’Amico, Anthony V., M.D., Ph.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20111115</creationdate><title>Race and Survival Following Brachytherapy-Based Treatment for Men With Localized or Locally Advanced Adenocarcinoma of the Prostate</title><author>Winkfield, Karen M., M.D., Ph.D ; Chen, Ming-Hui, Ph.D ; Dosoretz, Daniel E., M.D ; Salenius, Sharon A., M.P.H ; Katin, Michael, M.D ; Ross, Rudi, B.S ; D’Amico, Anthony V., M.D., Ph.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-90a1b87626783e8017e9f3b3c512db24de36d761565d541e2e42305587b87a443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adenocarcinoma - ethnology</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Aged</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>ANTIGENS</topic><topic>Black or African American</topic><topic>Black People</topic><topic>BRACHYTHERAPY</topic><topic>Brachytherapy - mortality</topic><topic>BYPASSES</topic><topic>CARCINOMAS</topic><topic>Cardiac comorbidity</topic><topic>Cause of Death</topic><topic>Cohort Studies</topic><topic>CORONARIES</topic><topic>DEATH</topic><topic>HAZARDS</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hispanic or Latino</topic><topic>Humans</topic><topic>Male</topic><topic>MEN</topic><topic>MORTALITY</topic><topic>MYOCARDIAL INFARCTION</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocardial Infarction - therapy</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>PROSTATE</topic><topic>Prostate brachytherapy</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - ethnology</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Racial disparities</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>Regression Analysis</topic><topic>Risk Factors</topic><topic>Socioeconomic Factors</topic><topic>Treatment Outcome</topic><topic>Treatment outcomes</topic><topic>White People</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Winkfield, Karen M., M.D., Ph.D</creatorcontrib><creatorcontrib>Chen, Ming-Hui, Ph.D</creatorcontrib><creatorcontrib>Dosoretz, Daniel E., M.D</creatorcontrib><creatorcontrib>Salenius, Sharon A., M.P.H</creatorcontrib><creatorcontrib>Katin, Michael, M.D</creatorcontrib><creatorcontrib>Ross, Rudi, B.S</creatorcontrib><creatorcontrib>D’Amico, Anthony V., M.D., Ph.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Winkfield, Karen M., M.D., Ph.D</au><au>Chen, Ming-Hui, Ph.D</au><au>Dosoretz, Daniel E., M.D</au><au>Salenius, Sharon A., M.P.H</au><au>Katin, Michael, M.D</au><au>Ross, Rudi, B.S</au><au>D’Amico, Anthony V., M.D., Ph.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Race and Survival Following Brachytherapy-Based Treatment for Men With Localized or Locally Advanced Adenocarcinoma of the Prostate</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2011-11-15</date><risdate>2011</risdate><volume>81</volume><issue>4</issue><spage>e345</spage><epage>e350</epage><pages>e345-e350</pages><issn>0360-3016</issn><issn>1879-355X</issn><eissn>1879-355X</eissn><abstract>Purpose We investigated whether race was associated with risk of death following brachytherapy-based treatment for localized prostate cancer, adjusting for age, cardiovascular comorbidity, treatment, and established prostate cancer prognostic factors. Methods The study cohort was composed of 5,360 men with clinical stage T1-3N0M0 prostate cancer who underwent brachytherapy-based treatment at 20 centers within the 21st Century Oncology consortium. Cox regression multivariable analysis was used to evaluate the risk of death in African-American and Hispanic men compared to that in Caucasian men, adjusting for age, pretreatment prostate-specific antigen (PSA) level, Gleason score, clinical T stage, year and type of treatment, median income, and cardiovascular comorbidities. Results After a median follow-up of 3 years, there were 673 deaths. African-American and Hispanic races were significantly associated with an increased risk of all-cause mortality (ACM) (adjusted hazard ratio, 1.77 and 1.79; 95% confidence intervals, 1.3–2.5 and 1.2–2.7; p < 0.001 and p = 0.005, respectively). Other factors significantly associated with an increased risk of death included age ( p < 0.001), Gleason score of 8 to 10 ( p = 0.04), year of brachytherapy ( p < 0.001), and history of myocardial infarction treated with stent or coronary artery bypass graft ( p < 0.001). Conclusions After adjustment for prostate cancer prognostic factors, age, income level, and revascularized cardiovascular comorbidities, African-American and Hispanic races were associated with higher ACM in men with prostate cancer. Additional causative factors need to be identified.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>21514066</pmid><doi>10.1016/j.ijrobp.2011.02.022</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2011-11, Vol.81 (4), p.e345-e350 |
| issn | 0360-3016 1879-355X 1879-355X |
| language | eng |
| recordid | cdi_osti_scitechconnect_22054389 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adenocarcinoma - ethnology Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Aged Androgen Antagonists - therapeutic use ANTIGENS Black or African American Black People BRACHYTHERAPY Brachytherapy - mortality BYPASSES CARCINOMAS Cardiac comorbidity Cause of Death Cohort Studies CORONARIES DEATH HAZARDS Hematology, Oncology and Palliative Medicine Hispanic or Latino Humans Male MEN MORTALITY MYOCARDIAL INFARCTION Myocardial Infarction - mortality Myocardial Infarction - therapy Neoplasm Grading Neoplasm Staging Prognosis PROSTATE Prostate brachytherapy Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - ethnology Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Racial disparities Radiology RADIOLOGY AND NUCLEAR MEDICINE Regression Analysis Risk Factors Socioeconomic Factors Treatment Outcome Treatment outcomes White People |
| title | Race and Survival Following Brachytherapy-Based Treatment for Men With Localized or Locally Advanced Adenocarcinoma of the Prostate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A38%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Race%20and%20Survival%20Following%20Brachytherapy-Based%20Treatment%20for%20Men%20With%20Localized%20or%20Locally%20Advanced%20Adenocarcinoma%20of%20the%20Prostate&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Winkfield,%20Karen%20M.,%20M.D.,%20Ph.D&rft.date=2011-11-15&rft.volume=81&rft.issue=4&rft.spage=e345&rft.epage=e350&rft.pages=e345-e350&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2011.02.022&rft_dat=%3Cproquest_osti_%3E901304605%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=901304605&rft_id=info:pmid/21514066&rft_els_id=1_s2_0_S0360301611003233&rfr_iscdi=true |